Iran Anti-Rheumatic Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Type of Molecule (Pharmaceuticals, Biopharmaceuticals) And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2022 To 2027

1. Introduction
1.1. Market Overview
1.2. COVID-19 impact
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Iran Antirheumatic Drug Market Analysis, By Type of Disease
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others

6. Iran Antirheumatic Drug Market Analysis, By Type of Molecule
6.1. Introduction
6.2. Pharmaceuticals
6.3. Biopharmaceuticals

7. Iran Antirheumatic Drug Market Analysis, By Sales Channel
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)

8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix

9. Company Profiles
9.1. GlaxoSmithKline plc
9.2. F. Hoffmann-La Roche Ltd
9.3. Novartis